Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas
Stre
… ProQR participated in the Chardan Genetic Medicines Conference panel discussion on “ ADAR RNA Editing: Unlocking … the next several quarters, including liver NHP data, at scientific conferences, as well as research related to …
… this program from Ionis Pharmaceuticals in October 2018. Scientific Updates During the second quarter of 2019, the … Company presented new data on the ProQR portfolio at three scientific conferences, including the annual meeting of … the Company presented at the 2019 annual Usher connections conference in July 2019. Business Updates In May 2019, …